Aarti also under FDA lens over GMP deviations at Indian site
This article was originally published in Scrip
Executive Summary
India's Aarti Drugs has joined a list of domestic firms hauled up by the US FDA over the recent past for good manufacturing practice (GMP) deviations at their manufacturing sites.